This study is a multicenter, prospective, observational research project. It is anticipated to enroll a total of 6,000 patients between February 1, 2025, and January 31, 2028 (with completion of one-year postoperative follow-up by January 31, 2029). Patients will be grouped according to different combinations of anticoagulant and antiplatelet drugs used postoperatively for PAD. The types, dosages, and duration of postoperative anticoagulant and antiplatelet drug use will be recorded. Follow-up assessments will be conducted at 1 month, 6 months, and 12 months postoperatively to document the occurrence of Major Adverse Cardiovascular Events (MACE) and Major Adverse Limb Events (MALE) in the enrolled patients.
1. History of PAD, or a history of intermittent claudication with an ankle/brachial blood pressure ratio < 0.9, or angiography-confirmed significant peripheral arterial stenosis (≥50%).
1. **Patients with a history of stroke within the past month** or a history of hemorrhagic or lacunar stroke.